Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome

American Journal of Human Genetics

Volumn 83, Issue 4, 2008, Pages 479-488

  Ortiz Abalia, Jon ^a,b   Sahún, Ignasi ^a,b   Altafaj, Xavier ^a,b   Andreu, Núria ^a,b   Estivill, Xavier ^a,c   Dierssen, Mara ^a,b   Fillat, Cristina ^a,b  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DYRK1A PROTEIN; PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN SYNDROME; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOTOR DYSFUNCTION; MOUSE; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CERCOPITHECUS AETHIOPS; COS CELLS; DEPENDOVIRUS; DOWN SYNDROME; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MODELS, GENETIC; NEURONS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RATS;

ADENO-ASSOCIATED VIRUS - 2; MURINAE; MUS;

EID: 53049095233     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajhg.2008.09.010     Document Type: Article

References (29)

1. Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.S., Toyoda A., Ishii K., Totoki Y., Choi D.K., et al. The DNA sequence of human chromosome 21. Nature 405 (2000) 311-319
2. Antonarakis S.E., and Epstein C.J. The challenge of Down syndrome. Trends Mol. Med. 12 (2006) 473-479
3. Dowjat W.K., Adayev T., Kuchna I., Nowicki K., Palminiello S., Hwang Y.W., and Wegiel J. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci. Lett. 413 (2007) 77-81
4. Guimera J., Casas C., Estivill X., and Pritchard M. Human minibrain homologue (MNBH/DYRK1): Characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. Genomics 57 (1999) 407-418
5. Becker W., Weber Y., Wetzel K., Eirmbter K., Tejedor F.J., and Joost H.G. Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J. Biol. Chem. 273 (1998) 25893-25902
6. Dierssen M., and de Lagran M.M. DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A): A gene with dosage effect during development and neurogenesis. ScientificWorldJournal 6 (2006) 1911-1922
7. Smith D.J., Stevens M.E., Sudanagunta S.P., Bronson R.T., Makhinson M., Watabe A.M., O'Dell T.J., Fung J., Weier H.U., Cheng J.F., et al. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat. Genet. 16 (1997) 28-36
8. Martinez de Lagran M., Altafaj X., Gallego X., Marti E., Estivill X., Sahun I., Fillat C., and Dierssen M. Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. Neurobiol. Dis. 15 (2004) 132-142
9. Ahn K.J., Jeong H.K., Choi H.S., Ryoo S.R., Kim Y.J., Goo J.S., Choi S.Y., Han J.S., Ha I., and Song W.J. DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol. Dis. 22 (2006) 463-472
10. Altafaj X., Dierssen M., Baamonde C., Marti E., Visa J., Guimera J., Oset M., Gonzalez J.R., Florez J., Fillat C., et al. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 10 (2001) 1915-1923
11. Arron J.R., Winslow M.M., Polleri A., Chang C.P., Wu H., Gao X., Neilson J.R., Chen L., Heit J.J., Kim S.K., et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441 (2006) 595-600
12. Warrington Jr. K.H., and Herzog R.W. Treatment of human disease by adeno-associated viral gene transfer. Hum. Genet. 119 (2006) 571-603
13. Sui G., Soohoo C., Affar el B., Gay F., Shi Y., and Forrester W.C. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99 (2002) 5515-5520
14. Fujita Y., Katagi J., Tabuchi A., Tsuchiya T., and Tsuda M. Coactivation of secretogranin-II and BDNF genes mediated by calcium signals in mouse cerebellar granule cells. Brain Res. Mol. Brain Res. 63 (1999) 316-324
15. Marti E., Altafaj X., Dierssen M., de la Luna S., Fotaki V., Alvarez M., Perez-Riba M., Ferrer I., and Estivill X. Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system. Brain Res. 964 (2003) 250-263
16. Salvetti A., Oreve S., Chadeuf G., Favre D., Cherel Y., Champion-Arnaud P., David-Ameline J., and Moullier P. Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. 9 (1998) 695-706
17. Brooks A.R., Harkins R.N., Wang P., Qian H.S., Liu P., and Rubanyi G.M. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J. Gene Med. 6 (2004) 395-404
18. McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B., et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. USA 105 (2008) 5868-5873
19. Campbell L.E., Hughes M., Budd T.W., Cooper G., Fulham W.R., Karayanidis F., Hanlon M.C., Stojanov W., Johnston P., Case V., et al. Primary and secondary neural networks of auditory prepulse inhibition: A functional magnetic resonance imaging study of sensorimotor gating of the human acoustic startle response. Eur. J. Neurosci. 26 (2007) 2327-2333
20. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl.) 156 (2001) 117-154
21. Fernandez F., Morishita W., Zuniga E., Nguyen J., Blank M., Malenka R.C., and Garner C.C. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10 (2007) 411-413
22. Costa A.C., Scott-McKean J.J., and Stasko M.R. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33 (2008) 1624-1632
23. Fotaki V., Dierssen M., Alcantara S., Martinez S., Marti E., Casas C., Visa J., Soriano E., Estivill X., and Arbones M.L. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol. Cell. Biol. 22 (2002) 6636-6647
24. Fotaki V., Martinez De Lagran M., Estivill X., Arbones M., and Dierssen M. Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity. Behav. Neurosci. 118 (2004) 815-821
25. Tejedor F., Zhu X.R., Kaltenbach E., Ackermann A., Baumann A., Canal I., Heisenberg M., Fischbach K.F., and Pongs O. minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron 14 (1995) 287-301
26. Moller R.S., Kubart S., Hoeltzenbein M., Heye B., Vogel I., Hansen C.P., Menzel C., Ullmann R., Tommerup N., Ropers H.H., et al. Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. Am. J. Hum. Genet. 82 (2008) 1165-1170
27. Okui M., Ide T., Morita K., Funakoshi E., Ito F., Ogita K., Yoneda Y., Kudoh J., and Shimizu N. High-level expression of the Mnb/Dyrk1A gene in brain and heart during rat early development. Genomics 62 (1999) 165-171
28. Martinez de Lagran M., Bortolozzi A., Millan O., Gispert J.D., Gonzalez J.R., Arbones M.L., Artigas F., and Dierssen M. Dopaminergic deficiency in mice with reduced levels of the dual-specificity tyrosine-phosphorylated and regulated kinase 1A, Dyrk1A(+/-). Genes Brain Behav. 6 (2007) 569-578
29. Hallett P.J., Spoelgen R., Hyman B.T., Standaert D.G., and Dunah A.W. Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J. Neurosci. 26 (2006) 4690-4700